1-2 of 2
Michelle Stevens-Brogan
Close
Sort by
Journal Articles

Efficacy and Safety of Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p Deletion: Results from the Phase II RESONATE™-17 Trial

Susan O'Brien, MD, Jeffrey A. Jones, MD, Steven Coutre, MD, Anthony R. Mato, MD, Peter Hillmen, MB, ChB, PhD, Constantine Tam, MD, Anders Osterborg, MD PhD, Tanya Siddiqi, MD, Michael J. Thirman, MD, Richard R. Furman, MD, Osman Ilhan, MD, Michael Keating, MBBS, Timothy G. Call, MD, Jennifer R. Brown, MD PhD, Michelle Stevens-Brogan, MS, Yunfeng Li, PhD, Maria Fardis, PhD MBA, Fong Clow, ScD, Danelle F. James, MD MAS, Alvina D. Chu, MD, Michael Hallek, MD, Stephan Stilgenbauer, MD
Journal: Blood
Blood (2014) 124 (21): 327.
https://doi.org/10.1182/blood.V124.21.327.327
Published: 2014
Journal Articles

Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up

Michael Wang, M.D., Simon A. Rule, MD, Peter Martin, MD, Andre Goy, MD, Rebecca Auer, MD, Brad S. Kahl, M.D., Wojciech Jurczak, Ranjana H. Advani, MD, Jorge Enrique E Romaguera, MD, Jesse McGreivy, MD, Fong Clow, ScD, Michelle Stevens-Brogan, Lori Kunkel, MD, Kristie A. Blum, MD
Journal: Blood
Blood (2012) 120 (21): 904.
https://doi.org/10.1182/blood.V120.21.904.904
Published: 2012